June 24, 2025
3 min watch
LAS VEGAS — On this Healio Video Perspective from Medical Trials on the Summit, SriniVas R. Sadda, MD, FARVO, discusses the challenges of utilizing the ellipsoid zone as a trial endpoint.
“It’s thrilling that the FDA a minimum of has indicated that the standing of the photoreceptors, their preservation over time, is a crucial endpoint for trials, however they didn’t actually get into the weeds about how can we really measure it,” he stated.
In accordance with Sadda, challenges with utilizing the ellipsoid zone (EZ) embrace inconsistent terminology for EZ integrity and points with visualization of the EZ band. In age-related macular degeneration, illness options comparable to drusen might have an effect on EZ evaluation.
Sadda urged that the EZ might not be a delicate marker for photoreceptor loss in contrast with different markers such because the outer nuclear layer.
“Even when you’ll be able to present with a remedy that the EZ is preserved, we don’t know whether or not that preserved EZ is practical,” Sadda stated.
Sources/Disclosures
Collapse
Sadda S. Alternatives and challenges for the EZ as a trial endpoint. Offered at: Medical Trials on the Summit; June 21, 2025; Las Vegas.
Disclosures:
Sadda reviews no related monetary disclosures.
